Major Shareholder Tang Capital Commits 9% Stake to Aurinia Merger

summarizeSummary

Tang Capital Management and Kevin Tang, holding 9.0% of Kezar Life Sciences, have entered into a Tender and Support Agreement, committing their shares to the acquisition by Aurinia Pharmaceuticals and rescinding their prior acquisition proposal.

check_boxKey Events

• Major Shareholder Support for Merger

  Tang Capital Management, LLC and Kevin Tang, who collectively beneficially own 664,314 shares representing 9.0% of Kezar Life Sciences' outstanding common stock, have entered into a Tender and Support Agreement.

• Commitment to Tender Shares

  The Reporting Persons have agreed to tender all of their shares in connection with the Agreement and Plan of Merger with Aurinia Pharmaceuticals, Inc., which was announced on March 30, 2026.

• Prior Acquisition Proposal Rescinded

  Concentra Biosciences, LLC, an entity controlled by Tang Capital, has formally rescinded its previous acquisition proposal to acquire 100% of Kezar Life Sciences' equity, originally sent on October 8, 2024.

auto_awesomeAnalysis

This Schedule 13D/A provides a crucial update following the announcement of Kezar Life Sciences' acquisition by Aurinia Pharmaceuticals on March 30, 2026. Tang Capital Management and Kevin Tang, a significant 9.0% shareholder, have formally agreed to tender their shares in support of the merger. This commitment from a major investor significantly increases the certainty of the acquisition's completion. Furthermore, Concentra Biosciences, LLC, controlled by Tang Capital, has rescinded its previous acquisition proposal, removing any potential competing bids and streamlining the merger process. The stock is currently trading near its 52-week high, reflecting the market's reaction to the merger news.